Fusion proteins are engineered molecules combining domains from two or more distinct proteins into a single polypeptide chain to endow new or enhanced biological functions. In antibody research and drug development, fusion proteins often incorporate an immunoglobulin framework with targeting, signaling, or effector domains such as cytokines, enzymes, or synthetic peptides.
Antibody fusion proteins (AFPs) offer pharmacological advantages such as prolonged serum half-life via FcRn-mediated recycling, enhanced targeting precision, and improved stability over conventional biologics. They are being explored for a wide range of indications including oncology, autoimmunity, infectious diseases, and neurodegeneration.
The field of antibody fusion proteins has evolved rapidly from early-generation Fc-fusion drugs to multifunctional drugs capable of fine-tuning immune responses. Clinically approved fusion proteins, such as etanercept (TNFR2-Fc), paved the way for a new class of therapeutics. Recent efforts have emphasized rational molecular design to overcome challenges like cytokine pleiotropy, systemic toxicity, and rapid clearance.
Recent reviews emphasize two trends:
Modular Immunocytokine Design: Antibody-cytokine fusion proteins are being engineered for selective immune activation, often using intramolecular designs to bias receptor signaling and extend half-life.
Payload Diversity: Beyond cytokines, payloads now include amyloid-reactive peptides, enzymes, toxins, and immune checkpoint modulators, broadening the utility of fusion formats.
A novel fusion protein-based strategy for antibody generation was described by Ware et al., addressing the longstanding challenge of targeting unstable protein complexes. The team engineered a fusion construct of BTLA and HVEM, two membrane proteins that form a transient complex relevant to immune regulation. By stabilizing the complex via genetic fusion, they facilitated successful monoclonal antibody production, enabling quantification of both individual and complexed protein forms in live cells.
This work represents an advancement in antibody discovery, especially for conformational or unstable epitopes. It opens new avenues for developing antibodies against transient protein complexes implicated in diseases such as lupus and lymphomas.
The fusion protein AT-02 (zamubafusp alfa) is an example the potential of AFPs in addressing amyloid diseases. AT-02 combines a humanized IgG1 with a pan-amyloid reactive peptide (p5R), targeting both amyloid fibrils and heparan sulfate glycans. Its high affinity for pathological amyloid structures across diverse subtypes enables it to act as an opsonin, enhancing phagocytosis and complement activation.
Preclinical studies demonstrated AT-02’s broad reactivity and ability to remain bound to amyloid deposits in vivo, motivating its evaluation in human trials for systemic amyloidosis (NCT05951049, NCT05521022). By eliminating the need for subtype-specific antibodies, this platform could streamline therapeutic development across heterogeneous amyloid diseases.
A new generation of trifunctional antibody-cytokine fusion proteins has been developed to co-deliver multiple cytokines, thereby enhancing immune synergy within the tumor microenvironment. Möller et al. created fusion constructs combining IL-15 with either IL-7 or IL-21 in various configurations. Their study showed that cytokine positioning within the construct critically influences function, with N-/C-terminal cytokine arrangements outperforming serial designs.
IL-15+IL-21 constructs, especially those with an scFv-based central antibody domain, enhanced IFN-γ release and cytotoxic activity in CD8+ T cells more effectively than monofunctional analogs. These findings suggest that spatially coordinated cytokine delivery is essential for maximizing therapeutic potential while minimizing off-target effects.
Fusion proteins are also gaining traction as biomarkers and therapeutic agents for Alzheimer’s disease (AD). Agustini et al. reviewed current developments where fusion proteins facilitate blood-brain barrier crossing, enable imaging of pathological proteins (Aβ and tau), and act as therapeutic carriers.
Several constructs have demonstrated efficacy in animal models for delivering therapeutic agents into the CNS, reducing protein aggregation, and modulating immune responses. This diagnostic and therapeutic potential positions fusion proteins as ideal candidates for next-generation AD interventions.
Fusion proteins are redefining the frontiers of antibody-based therapeutics. Innovations in structural design, target selection, and payload integration are converging to create a diverse pipeline of multifunctional agents. Key areas for future development include:
Enhanced tissue-specific targeting
Minimization of immunogenicity and systemic toxicity
Controlled multi-receptor engagement strategies
Clinical translation of combinatorial payloads
As understanding of immune and disease biology deepens, fusion proteins are expected to play a central role in shaping personalized, precision immunotherapies across a broad spectrum of indications.
Biointron’s 2026 Antibody Industry Outlook aims to explore the events and trends……
Antibody-drug conjugates (ADCs) rely critically on the chemical linker as the m……
Despite comprising the largest family of druggable membrane proteins, only three……
You can also contact us on the Scientist and Science Exchange marketplaces.
